dc.contributor.author | Karunamuni, RA | |
dc.contributor.author | Huynh-Le, M-P | |
dc.contributor.author | Fan, CC | |
dc.contributor.author | Eeles, RA | |
dc.contributor.author | Easton, DF | |
dc.contributor.author | Kote-Jarai, Z | |
dc.contributor.author | Amin Al Olama, A | |
dc.contributor.author | Benlloch Garcia, S | |
dc.contributor.author | Muir, K | |
dc.contributor.author | Gronberg, H | |
dc.contributor.author | Wiklund, F | |
dc.contributor.author | Aly, M | |
dc.contributor.author | Schleutker, J | |
dc.contributor.author | Sipeky, C | |
dc.contributor.author | Tammela, TLJ | |
dc.contributor.author | Nordestgaard, BG | |
dc.contributor.author | Key, TJ | |
dc.contributor.author | Travis, RC | |
dc.contributor.author | Neal, DE | |
dc.contributor.author | Donovan, JL | |
dc.contributor.author | Hamdy, FC | |
dc.contributor.author | Pharoah, P | |
dc.contributor.author | Pashayan, N | |
dc.contributor.author | Khaw, K-T | |
dc.contributor.author | Thibodeau, SN | |
dc.contributor.author | McDonnell, SK | |
dc.contributor.author | Schaid, DJ | |
dc.contributor.author | Maier, C | |
dc.contributor.author | Vogel, W | |
dc.contributor.author | Luedeke, M | |
dc.contributor.author | Herkommer, K | |
dc.contributor.author | Kibel, AS | |
dc.contributor.author | Cybulski, C | |
dc.contributor.author | Wokolorczyk, D | |
dc.contributor.author | Kluzniak, W | |
dc.contributor.author | Cannon-Albright, L | |
dc.contributor.author | Brenner, H | |
dc.contributor.author | Schöttker, B | |
dc.contributor.author | Holleczek, B | |
dc.contributor.author | Park, JY | |
dc.contributor.author | Sellers, TA | |
dc.contributor.author | Lin, H-Y | |
dc.contributor.author | Slavov, C | |
dc.contributor.author | Kaneva, R | |
dc.contributor.author | Mitev, V | |
dc.contributor.author | Batra, J | |
dc.contributor.author | Clements, JA | |
dc.contributor.author | Spurdle, A | |
dc.contributor.author | Australian Prostate Cancer BioResource (APCB), | |
dc.contributor.author | Teixeira, MR | |
dc.contributor.author | Paulo, P | |
dc.contributor.author | Maia, S | |
dc.contributor.author | Pandha, H | |
dc.contributor.author | Michael, A | |
dc.contributor.author | Mills, IG | |
dc.contributor.author | Andreassen, OA | |
dc.contributor.author | Dale, AM | |
dc.contributor.author | Seibert, TM | |
dc.contributor.author | PRACTICAL Consortium, | |
dc.date.accessioned | 2021-08-20T14:44:44Z | |
dc.date.available | 2021-08-20T14:44:44Z | |
dc.date.issued | 2020-10-01 | |
dc.identifier.citation | European journal of human genetics : EJHG, 2020, 28 (10), pp. 1467 - 1475 | |
dc.identifier.issn | 1018-4813 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4770 | |
dc.identifier.eissn | 1476-5438 | |
dc.identifier.doi | 10.1038/s41431-020-0664-2 | |
dc.description.abstract | We determined the effect of sample size on performance of polygenic hazard score (PHS) models in prostate cancer. Age and genotypes were obtained for 40,861 men from the PRACTICAL consortium. The dataset included 201,590 SNPs per subject, and was split into training and testing sets. Established-SNP models considered 65 SNPs that had been previously associated with prostate cancer. Discovery-SNP models used stepwise selection to identify new SNPs. The performance of each PHS model was calculated for random sizes of the training set. The performance of a representative Established-SNP model was estimated for random sizes of the testing set. Mean HR98/50 (hazard ratio of top 2% to average in test set) of the Established-SNP model increased from 1.73 [95% CI: 1.69-1.77] to 2.41 [2.40-2.43] when the number of training samples was increased from 1 thousand to 30 thousand. Corresponding HR98/50 of the Discovery-SNP model increased from 1.05 [0.93-1.18] to 2.19 [2.16-2.23]. HR98/50 of a representative Established-SNP model using testing set sample sizes of 0.6 thousand and 6 thousand observations were 1.78 [1.70-1.85] and 1.73 [1.71-1.76], respectively. We estimate that a study population of 20 thousand men is required to develop Discovery-SNP PHS models while 10 thousand men should be sufficient for Established-SNP models. | |
dc.format | Print-Electronic | |
dc.format.extent | 1467 - 1475 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGERNATURE | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Australian Prostate Cancer BioResource (APCB) | |
dc.subject | PRACTICAL Consortium | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Proportional Hazards Models | |
dc.subject | Sample Size | |
dc.subject | Multifactorial Inheritance | |
dc.subject | Polymorphism, Single Nucleotide | |
dc.subject | Models, Genetic | |
dc.subject | Male | |
dc.subject | Clinical Trials as Topic | |
dc.subject | Genome-Wide Association Study | |
dc.title | The effect of sample size on polygenic hazard models for prostate cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-05-22 | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1038/s41431-020-0664-2 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of human genetics : EJHG | |
pubs.issue | 10 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.publication-status | Published | |
pubs.volume | 28 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Oncogenetics | |
icr.researchteam | Oncogenetics | |
dc.contributor.icrauthor | Eeles, Rosalind | |
dc.contributor.icrauthor | Kote-Jarai, Zsofia | |